US FDA Approves Obesity Treatment Contrave; Takeda Has Marketing Rights

The US FDA announced on September 10 that it has approved Orexigen Therapeutics’s obesity treatment Contrave (naltrexone HCl + bupropion HCl), extended-release tablets, to which Takeda Pharmaceutical will hold the marketing rights in the US. Contrave is a combination of...read more